Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $28,463.36 in Stock

by · The Markets Daily

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 76,928 shares of the stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $0.37, for a total transaction of $28,463.36. Following the transaction, the director directly owned 300,283 shares of the company’s stock, valued at $111,104.71. This represents a 20.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

  • On Monday, June 8th, Luke Evnin sold 60,547 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total transaction of $24,218.80.
  • On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.40, for a total transaction of $9,978.40.
  • On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.44, for a total transaction of $8,831.68.
  • On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.42, for a total transaction of $12,494.58.
  • On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $13,317.75.
  • On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total transaction of $37,815.73.
  • On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $14,650.20.
  • On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total transaction of $12,741.08.
  • On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.48, for a total transaction of $38,808.96.
  • On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $31,936.50.

Werewolf Therapeutics Price Performance

HOWL traded down $0.01 during midday trading on Wednesday, reaching $0.37. 169,732 shares of the company’s stock were exchanged, compared to its average volume of 466,070. Werewolf Therapeutics, Inc. has a 1-year low of $0.36 and a 1-year high of $2.38. The stock has a market capitalization of $17.74 million, a PE ratio of -0.29 and a beta of 0.29. The business’s 50-day moving average price is $0.69 and its 200 day moving average price is $0.72.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. As a group, analysts expect that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on HOWL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $3.75.

Check Out Our Latest Stock Report on HOWL

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Regal Investment Advisors LLC raised its stake in Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after buying an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. raised its stake in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after buying an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics during the second quarter valued at approximately $48,000. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics during the first quarter valued at approximately $79,000. Finally, Bridgeway Capital Management LLC raised its stake in Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after buying an additional 62,414 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.

Read More